Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
Investing.com -- Silexion Therapeutics Corp. (NASDAQ:SLXN) stock soared 400% after the company reported positive preclinical data for its pancreatic cancer drug SIL204, demonstrating the treatment’s ability to reach major metastatic sites following systemic administration.
The clinical-stage biotechnology company, which focuses on RNA interference therapies for KRAS-driven cancers, announced that subcutaneously administered SIL204 successfully reached all primary sites of pancreatic cancer metastasis and showed anti-tumor activity in a mouse model. The study confirmed the drug distributed to key organs where pancreatic cancer commonly spreads, with measurable reductions in tumor burden observed across multiple sites.
Key findings from the study showed SIL204 distributed to all major metastatic sites following a single subcutaneous injection at a mid-range human equivalent dose planned for clinical trials. Reductions in tumor burden were observed at day 7 across all evaluated organs, with statistically significant reductions in the peritoneum and lung.
The liver, which is the most common site of pancreatic cancer metastasis, also showed measurable reduction in tumor burden. These results are particularly significant as over 80% of pancreatic cancer mortality is attributed to metastatic disease.
"These findings provide additional validation for a critical component of our dual-route administration strategy - the ability of subcutaneously delivered SIL204 to reach metastatic sites throughout the body," said Mitchell Shirvan, Chief Scientific Officer of Silexion.
The company is also conducting expanded tissue culture studies across multiple cancer types and KRAS mutations to further characterize SIL204’s pan-KRAS potential.
Silexion remains on track to initiate Phase 2/3 clinical trials evaluating its dual-route administration approach in the first half of 2026, with regulatory submissions planned for the fourth quarter of 2025 and first quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.